Abstract
Patients with atopic dermatitis (AD) have increased risk of herpes simplex (HS) infection. Eczema herpeticum (EH) is a serious complication of HS. In a published safety analysis of abrocitinib, HS was reported in 5.9% (116; IR 11.83) and 6.1% (54; IR 8.73) and EH was reported in 0.4% (8; IR 0.78) and 1.7% (15; IR 2.34) of patients treated with abrocitinib 200 mg (N=1971) and 100 mg (N=885), respectively. Two EH events occurred in patients with IGA score <2 (both 100 mg). This post hoc analysis further characterized HS and EH in the above analysis of pooled data from patients with moderate to severe AD receiving abrocitinib 200 mg or 100 mg in the phase 2b (NCT02780167) and phase 3 JADE MONO-1 (NCT03349060), MONO-2 (NCT03575871), COMPARE (NCT03720470), REGIMEN open-label induction phase (NCT03627767), and EXTEND long-term extension (NCT03422822) trials (data cutoff: April 22, 2020).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
